Here's What Analysts Think About ADMA Biologics (ADMA)
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the best small cap stocks to buy for 10x potential. On May 7, Mizuho lowered the price target on ADMA Biologics, Inc.
Adma Biologics Inc. (ADMA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 5,810,642 | $52,353,885 | +282% | 0.01% |
| 2. | Caligan Partners David Johnson | 4,756,511 | $42,856,164 | +58% | 2.85% |
| 3. | Millennium Management Israel Englander | 3,434,449 | $30,944,385 | +413% | 0.01% |
| 4. | Point72 Asset Management Steve Cohen | 3,288,757 | $29,631,701 | +735% | 0.04% |
| 5. | Ranger Investment Management Conrad Doenges (Cio) | 2,283,810 | $20,577,128 | -1% | 1.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.01 | 12,500 | $100,125.00 | 513,884 | 2026-05-12 | Filing | |
| $8.01 | 12,500 | $100,125.00 | 501,384 | 2026-05-11 | Filing | |
| $15.39 | 7,000 | $107,730.00 | 2,045,730 | 2026-03-06 | Filing | |
| $15.67 | 7,000 | $109,690.00 | 2,038,730 | 2026-03-05 | Filing | |
| $3.71 | 130,000 | $482,144.00 | 443,265 | 2023-08-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.16 | 6,000 | $90,960.00 | 2,112,777 | 2026-03-16 | Filing | |
| $15.16 | 15,000 | $227,400.00 | 2,118,777 | 2026-03-16 | Filing | |
| $15.63 | 10,096 | $157,800.48 | 466,600 | 2026-03-09 | Filing | |
| $16.08 | 6,000 | $96,480.00 | 2,284,379 | 2026-02-17 | Filing | |
| $16.08 | 15,000 | $241,200.00 | 2,290,379 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,830,774 | $331,845,274 | 0.01% | |
| 2. | 14,084,205 | $126,898,687 | 0% | |
| 3. | 11,191,116 | $100,831,955 | 0.02% | |
| 4. | 10,306,871 | $92,864,908 | 0% | |
| 5. | 8,868,657 | $79,906,600 | 0% |
News See All
Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best healthcare stocks to buy for the long term. Canaccord cut the price target on ADMA Biologics Inc.
15 Best Small Cap Stocks to Buy for 10x Potential
On May 11, Dan Niles, Niles Investment Management founder, appeared on CNBC’s ‘The Exchange’ to talk about his view on equity markets while conducting a comparison with the prior periods.
10 Best Healthcare Stocks to Buy for the Long Term
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared...
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics First Quarter 2026 Financial Results and Business Update Conference Call on Wednesday, May 6, 2026.
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends
TheFly reported on April 21 that Canaccord Genuity initiated coverage of ADMA with a Buy rating and set a price target of $21.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best low priced biotech stocks to invest in. Mizuho cut the price target on ADMA Biologics Inc.
Cantor Fitzgerald Downgrades ADMA Biologics Inc. (ADMA) to Neutral From Overweight
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the most undervalued biotech stocks to buy right now. Cantor Fitzgerald downgraded ADMA Biologics Inc.
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Hedge Fund Resource Center